Published by: One Zero Written by: Emily Mullin Antiretroviral drugs make HIV manageable, but gene therapies could eliminate the virus altogether — provided the treatments can be made safe and economical In the mid-1990s, scientists made a curious but remarkable discovery: A man named Stephen Crohn seemed virtually immune to HIV. In the years before that discovery,… [Read More]
Montgomery Magazine: “Jeffrey Galvin’s BioTech Firm May Be on The Verge of Curing HIV/AIDS”
Published by: Montgomery Magazine | Issue: August – September 2019, Page 42 Written by: Jeff Thoreson | Photograph by: Kevin Allen A 3D RENDERING OF HIV VIRUS IN BLOOD STREAM Jeffrey Galvin has been a computer nerd since the seventh grade. Way back in the 1970s era of mainframes, he became interested not so much… [Read More]
HIV Cure Program of American Gene Technologies Adds University of Maryland School of Medicine’s Institute of Human Virology as New Study Site to Support the Development of a Cell and Gene Therapy for HIV
ROCKVILLE, Md. — American Gene Technologies (AGT), a leading gene and cell therapy company based in Rockville, MD, selected the Institute of Human Virology (IHV) at the University of Maryland School of Medicine (UMSOM) as a new clinical site for its non-IND study, AGT-CS168, to collect clinical specimens from HIV positive individuals. AGT will use… [Read More]
C&EN: “With Several Long-acting HIV Treatments In The Works, The Newest Drugs Emphasize Convenience”
Published by: C&EN on May 12, 2019, In Volume 97, Issue 19. Written by: Megha Satyanarayana Lionel Hillard’s boss asked him to come into his office. It was the late 1980s in Dallas. The then 29-year-old was a medical assistant at a busy clinic with a room full of patients. But the doctor who ran… [Read More]
HIV Cure Program Patent Granted To American Gene Technologies
ROCKVILLE, Md., May 21, 2019 (GLOBE NEWSWIRE) — American Gene Technologies, a leading gene and cell therapy company based in Rockville, Md., was granted a second patent for its unique molecule, methods, and cell process for its HIV program. This patent further protects AGT’s lentiviral vector and proprietary process for generating autologous cell products to treat HIV… [Read More]
Second Patient Cured of HIV and The Implications for American Gene Technologies’s AGT103-T
ROCKVILLE, MD, UNITED STATES, March 8, 2019 / American Gene Technologies (AGT) is pleased to see the release of information about a second individual cured of HIV in London–recently reported in the Wall Street Journal and New York Times. The patient was treated with a bone marrow transplant from a CCR5-Δ32 donor. The London Patient… [Read More]
American Gene Technologies Signs Research Agreement with NIAID for Experimental HIV/AIDS Cure Strategy
AGT signed Research Collaboration Agreement with National Institute of Allergy and Infectious Diseases for studies on AGT’s cell and gene therapy for HIV/AIDS. ROCKVILLE, MD, UNITED STATES, February 14, 2019 /EINPresswire.com/ — American Gene Technologies (AGT) recently signed a Research Collaboration Agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the… [Read More]
American Gene Technologies (AGT) Granted Three New Patents in its HIV Cure and Immuno-oncology Programs
ROCKVILLE, MD, UNITED STATES, August 22, 2018 /EINPresswire.com/ — AGT announces the receipt of three foundational patents. Two new patents focus on the immuno-oncology program and add to AGT’s broad protection for its unique process of activating gamma delta T cells to attack solid tumors (“Methods and Composition for the Activation of Gamma Delta T… [Read More]
American Gene Technologies Congratulates Robert Redfield, M.D., on His Appointment as Director of the Centers for Disease Control and Prevention
ROCKVILLE, Md., March 28, 2018 (GLOBE NEWSWIRE) — American Gene Technologies International Inc. (AGT), a leading gene and cell therapy company, today congratulates Robert R. Redfield, M.D., on his appointment as the Director of the Centers for Disease Control and Prevention (CDC). Dr. Redfield has served as an advisor to AGT since 2011 and later became chair… [Read More]
BioWorld Reports American Gene Technologies’s Progress Toward an HIV cure
Newsletter Vol. 29, No. 18, Pg. 2 January 26, 2018 On January 26, 2018, BioWorld, The Daily Biopharmaceutical Newscource, published this story: American Gene Technologies International Inc. (AGT), of Rockville, Md., disclosed completion of the pilot runs of its HIV cure automated cell processing protocol. That completes a key milestone of the firm’s planned… [Read More]
American Gene Technologies Announces Progress toward Phase I Clinical Trial of AGT103-T for HIV cure
Completes process development for the AGT103-T automated cell manufacturing protocol ROCKVILLE, MD, January 25, 2018 — American Gene Technologies International Inc. (AGT), a leading gene and cell therapy company, today announced completion of the pilot runs of its HIV cure automated cell processing protocol. This completes a key milestone of AGT’s planned Phase I clinical trial… [Read More]
AGT CSO, David Pauza, to Present HIV cure data At The Cell & Gene Meeting on the Mesa
ROCKVILLE, MD., September. 26, 2017 (GLOBE NEWSWIRE) — American Gene Technologies International Inc. (AGT), a gene technology company focusing on a lentiviral delivery platform, today announced that Chief Science Officer C. David Pauza, Ph.D., will present at the upcoming Cell & Gene Meeting on the Mesa being held from October 4-6, 2017, in La Jolla, CA…. [Read More]
